Hartaj Singh
Stock Analyst at Oppenheimer
(1.38)
# 3,458
Out of 4,900 analysts
103
Total ratings
37.25%
Success rate
-11.38%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $123 → $45 | $18.21 | +147.12% | 11 | Jun 20, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $547.96 | +64.25% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $109.06 | +14.62% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $464.20 | - | 17 | Dec 19, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $6.31 | +343.74% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $293.24 | +104.61% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $31.58 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $2.08 | +380.77% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.78 | +3,270.79% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.70 | +429.41% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.31 | +2,953.44% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $6.37 | +245.37% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.90 | +34,110.53% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $24.36 | +23.15% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jun 20, 2025
Maintains: Outperform
Price Target: $123 → $45
Current: $18.21
Upside: +147.12%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $547.96
Upside: +64.25%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $109.06
Upside: +14.62%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $464.20
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $6.31
Upside: +343.74%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $293.24
Upside: +104.61%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $31.58
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $2.08
Upside: +380.77%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.78
Upside: +3,270.79%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.70
Upside: +429.41%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.31
Upside: +2,953.44%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $6.37
Upside: +245.37%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.90
Upside: +34,110.53%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $24.36
Upside: +23.15%